Raman Spectroscopy to Diagnose Alzheimer’s Disease and Dementia with Lewy Bodies in Blood

Accurate identification of Alzheimer’s disease (AD) is still of major clinical importance considering the current lack of noninvasive and low-cost diagnostic approaches. Detection of early stage AD is particularly desirable as it would allow early intervention or recruitment of patients into clinical trials. There is also an unmet need for discrimination of AD from dementia with Lewy bodies (DLB), as many cases of the latter are misdiagnosed as AD. Biomarkers based on a simple blood test would be useful in research and clinical practice. Raman spectroscopy has been implemented to analyze blood plasma of a cohort that consisted of early stage AD, late-stage AD, DLB, and healthy controls. Classification algorithms achieved high accuracy for the different groups: early stage AD <i>vs</i> healthy with 84% sensitivity, 86% specificity; late-stage AD <i>vs</i> healthy with 84% sensitivity, 77% specificity; DLB <i>vs</i> healthy with 83% sensitivity, 87% specificity; early-stage AD <i>vs</i> DLB with 81% sensitivity, 88% specificity; late-stage AD <i>vs</i> DLB with 90% sensitivity, 93% specificity; and lastly, early-stage AD <i>vs</i> late-stage AD 66% sensitivity and 83% specificity. G-score values were also estimated between 74% and 91%, demonstrating that the overall performance of the classification model was satisfactory. The wavenumbers responsible for differentiation were assigned to important biomolecules, which can serve as a panel of biomarkers. These results suggest a cost-effective, blood-based test for neurodegeneration in dementias